Adlai Nortye
ANLANL · Stock Price
Historical price data
Overview
Adlai Nortye is a clinical-stage biotech focused on developing innovative oncology therapies, with a core strategy of in-licensing and advancing mid-to-late-stage assets into new, high-need indications. Its most advanced candidate, buparlisib (AN2025), is in a pivotal global Phase 3 trial for head and neck squamous cell carcinoma (HNSCC). The company aims to address significant unmet medical needs by modulating the tumor microenvironment and overcoming resistance to standard treatments like anti-PD-1 therapy.
Technology Platform
A strategic therapeutic development platform built on three pillars: in-licensing of clinical-stage oncology assets for development in new indications, a focus on modulating the tumor microenvironment, and internal discovery of novel drug candidates.
Pipeline
8| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Buparlisib & Paclitaxel | Head and Neck Cancer | Phase 3 | |
| AN9025 oral capsule | Solid Tumors (Phase 1) | Phase 1 | |
| E7046 + capecitabine + folinic acid/5-FU/oxaliplatin (mFOLFO... | Neoadjuvant Therapy in Rectal Cancer | Phase 1 | |
| Pelareorep | Advanced or Metastatic Breast Cancer | Phase 1 | |
| AN0025 | Esophageal Cancer | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
Adlai Nortye competes in intensely crowded fields, including PI3K inhibitors and novel immuno-oncology agents, against large pharmaceutical companies and well-funded biotechs. Differentiation will require demonstrating superior efficacy or novel mechanisms of action in clinical trials.